Radiation Therapy for pT2N1 Tongue Cancer

Rationale for Radiation Therapy

Adjuvant postoperative radiotherapy should be delivered to the tumor bed and involved, dissected lymph node regions at once-daily fractionation to a total dose of 56 to 60 Gy in the absence of primary site positive margins and extracapsular nodal extension, as recommended by the American Society of Clinical Oncology 1, 3
The presence of nodal disease (N1) represents a significant risk factor for locoregional recurrence, making adjuvant radiation therapy an important component of treatment, according to the American Cancer Society 4
For pT2N1 disease, radiation therapy helps address the risk of microscopic disease that may remain after surgical resection, as stated by the American Society of Clinical Oncology 2

Standard fractionation of 2 Gy per fraction once daily is recommended by the American Society of Clinical Oncology 3
Total dose should be between 56-60 Gy to the tumor bed and involved lymph node regions, as recommended by the American Society of Clinical Oncology 1, 2
If microscopically positive margins or extracapsular nodal extension are present, the dose should be increased to 60-66 Gy, according to the American Society of Clinical Oncology 3

For well-lateralized tumors, unilateral radiotherapy may be considered for T1-T2 N0-N1 nodal category disease, as suggested by the American Society of Clinical Oncology 5
However, for tongue cancers that cross midline or have bilateral lymphatic drainage, bilateral treatment fields are typically required, according to the American Cancer Society 4
Concurrent systemic therapy may be considered for patients with T1-T2 N1 disease who are at particularly significant risk for locoregional recurrence, though this recommendation is conditional with low-quality evidence, as stated by the American Cancer Society 4, 6

Radiation-induced xerostomia is a common side effect, though modern techniques like IMRT can reduce its severity, as reported by the National Comprehensive Cancer Network 7
Regular assessment of thyroid function (TSH levels every 6-12 months) is recommended as hypothyroidism occurs in 20-25% of patients receiving neck irradiation, according to the National Comprehensive Cancer Network 7

Delaying the start of radiation therapy beyond 6 weeks after surgery can negatively impact outcomes, as warned by the American Society of Clinical Oncology 3
Failure to consider patient factors such as performance status and comorbidities when determining treatment intensity, as advised by the American Cancer Society 4
Not completing the full course of radiation therapy can compromise disease control, as emphasized by the American Society of Clinical Oncology 1